Summary of product characteristics
Summary of product characteristics (SmPCs) documents are available below. Pharmaceutical products described in this section are all prescription-only medicines (POMs) and include:
A fusion inhibitor for the treatment of HIV infection
A protease inhibitor for the treatment of HIV infection
Two different formulations of saquinavir, a protease inhibitor for the treatment of HIV infection
(peginterferon alfa-2a [40KD])
PEGASYS is a pegylated form of interferon alfa-2a for the treatment of HCV infection.
COPEGUS is a guanosine analogue that is used in combination with interferon-based therapy for the treatment of hepatitis C virus infection
(valganciclovir HCl tablets)
Valcyte is the oral pro-drug of Roche’s Cymevene (ganciclovir) used for the treatment of CMV infection.
Please note that information provided on any of the products listed above is
NOT INTENDED FOR PHYSICIANS IN COUNTRIES WHERE THE PRODUCTS ARE NOT LICENSED FOR USE.
Before reviewing product information contained in this section, please consult your relevant regulatory authorities if you are unsure of the approval status of any of these products in your country.
If you have any questions regarding any Roche HIV products, please e-mail: